Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

China flag China · Delayed Price · Currency is CNY
65.48
-0.43 (-0.65%)
Mar 9, 2026, 3:00 PM CST
-19.25%
Market Cap 5.13B
Revenue (ttm) 911.30M
Net Income (ttm) 218.28M
Shares Out 78.31M
EPS (ttm) 2.75
PE Ratio 23.81
Forward PE n/a
Dividend 2.00 (3.03%)
Ex-Dividend Date Oct 16, 2025
Volume 457,252
Average Volume 343,926
Open 65.99
Previous Close 65.91
Day's Range 64.04 - 65.99
52-Week Range 60.40 - 84.72
Beta 0.41
RSI 39.16
Earnings Date Apr 20, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te... [Read more]

Sector Healthcare
Founded 2009
Employees 960
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688606
Full Company Profile

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 911.30 million, an increase of 5.16% compared to the previous year's 866.58 million. Earnings were 218.28 million, a decrease of -27.83%.

Financial Statements

News

There is no news available yet.